29.11.2020, 2010 Zeichen
Another strong week for our ATX, reaching 2600 Points, Do&Co and Palfinger gained more than ten per cent: News came from UBM Development (2), Aventa, S Immo AG, Fabasoft, Andritz, CA Immo, Immofinanz, Marinomed, SBO, Vienna Insurance Group, Warimpex, Pierer Mobility, Biogena, Agrana.
BSNgine weekly Spitout: The ATX up 3,85% to 2.598,96 points this week. Year-to-date the ATX is now at -18,45%. Up to now there were 109 days with a positive and 123 with a negative gain. From the year-high we are 19,52% away, from the low 59,36%. Statistically the best weekday so far 2020 is Tuesday with 0,45%, the weakest is Thursday with -0,53%.
These are the best-performers this week: DO&CO 12,54% in front of Palfinger 11,18% and Immofinanz 9,38%. And the following stocks performed worst: Wienerberger -3,59% in front of Strabag -2,99% and Rosenbauer -2,36%.
Further highlights this week: Österreichische Post for 6 days in a row up (8,72% gain from 28,1 to 30,55), also Erste Group 5 days up (6,57% gain from 23,44 to 24,98), AT&S 4 days up (5,87% gain from 19,6 to 20,75), Addiko Bank 3 days up (6,38% gain from 9,25 to 9,84), Andritz 3 days up (4,17% gain from 33,54 to 34,94), Wienerberger 3 days down (3,75% loss from 24,56 to 23,64), Strabag 3 days down (4,83% loss from 29 to 27,6), Rosenbauer 3 days down (1,84% loss from 38 to 37,3), OMV 3 days down (3,47% loss from 30,58 to 29,52).
Best-performers year-to-date as of now: Semperit 113,64% (last year: 11,85 percent) followed by Verbund 31,87% (last year: 20,14 percent) and Mayr-Melnhof 22,41% (last year: 8,73 percent). And the worst-performing stocks year-to-date: Kapsch TrafficCom -56,45% (Vorjahr: -13,68 percent), followed by SBO -43,44% (Vorjahr: -12,29 percent) and OMV -41,05% (Vorjahr: 30,93 percent).
High above the MA200: Semperit 59,44%, Lenzing 45,94% and Verbund 34,23%.
Down under the MA200: Kapsch TrafficCom -21,93%, Warimpex -6,82% and Porr -4,82%.
(From the 21st Austria weekly https://www.boerse-social.com/21staustria (28/11/2020)
ABC Audio Business Chart #101: Die verborgene 13-Billionen-Welt der Private Markets (Josef Obergantschnig)
Evotec
Evotec ist ein Wirkstoffforschungs- und -entwicklungsunternehmen, das in Forschungsallianzen und Entwicklungspartnerschaften mit Pharma- und Biotechnologieunternehmen, akademischen Einrichtungen, Patientenorganisationen und Risikokapitalgesellschaften Ansätze zur Entwicklung neuer pharmazeutischer Produkte vorantreibt.
>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner